SCHEMBL3864245

SCHEMBL3864245

O=C(O)c1cc2c(cc1Cl)OC(F)(F)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
CASP1 P29466 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CNR1 P21554 1/20 0.40
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA13 Q8N1Q1 1/20 0.40
CISD1 Q9NZ45 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31726105 0.81 IDO1 (0.43) ALDH1A1CTNNB1WNT3AMRGPRX4KDM4E
SCHEMBL20638691 0.80 ALDH1A1 (0.43) ALDH1A1TSHRTP53CASP1SMN1; SMN2
SCHEMBL31697194 0.78 SMN1; SMN2 (0.54) TSHRSMN1; SMN2CNR1CTNNB1WNT3A
SCHEMBL3863958 0.78 SMN1; SMN2 (0.54) TSHRSMN1; SMN2CNR1CTNNB1WNT3A
SCHEMBL29397048 0.78 CTNNB1 (0.43) ALDH1A1CNR1CTNNB1WNT3AMRGPRX4
SCHEMBL25028468 0.78 CTNNB1 (0.43) ALDH1A1CNR1CTNNB1WNT3AMRGPRX4
SCHEMBL8759431 0.77 ALPL (0.48) TSHRCTNNB1WNT3ANPC1RAB9A
SCHEMBL5278435 0.74 CTNNB1 (0.37) CTNNB1WNT3AMRGPRX4KDM4EHDAC4
SCHEMBL4472381 0.73 ALDH1A1 (0.48) ALDH1A1TSHRTP53CASP1SMN1; SMN2
SCHEMBL31726102 0.73 DTYMK (0.44) ALDH1A1TSHRCTNNB1WNT3ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595876-B1 Process for the preparation of derivatives of difluorobenzo-(1,3)-dioxole-5-carboxylic acid SALTIGO GMBH (DE) 2007-12-12 EP claimed
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 US disclosed
EP-3651752-B1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-11-20 EP disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-11603351-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-14 US disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 US disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 US disclosed
EP-3651752-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2020-05-20 EP disclosed
US-10647661-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-12 US disclosed
CN-111065383-A Carboxamides useful as sodium channel modulators 沃泰克斯药物股份有限公司 2020-04-24 CN disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 US disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 US disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 WO disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 WO disclosed
US-7524976-B2 Process for preparing difluorobenzo-1,3-dioxole-5-carboxylic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2009-04-28 US disclosed
EP-1595876-B1 Process for the preparation of derivatives of difluorobenzo-(1,3)-dioxole-5-carboxylic acid SALTIGO GMBH (DE) 2007-12-12 EP disclosed
US-20050277692-A1 Process for preparing difluorobenzo-1,3-dioxole-5-carboxylic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2005-12-15 US disclosed
EP-1595876-A1 Process for the preparation of derivatives of difluorobenzo-(1,3)-dioxole-5-carboxylic acid Lanxess Deutschland GmbH (DE) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603351-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ALDH1A1 2665/4885TSHR 3163/4885TP53 4840/4885
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A ALDH1A1 2665/4885TSHR 3163/4885TP53 4840/4885
US-10647661-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ALDH1A1 2665/4885TSHR 3163/4885TP53 4840/4885
US-20050277692-A1 Process for preparing difluorobenzo-1,3-dioxole-5-carboxylic acid derivatives BROX, DDT, DAO ALDH1A1 351/4885TSHR 3905/4885TP53 929/4885
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A ALDH1A1 2665/4885TSHR 3163/4885TP53 4840/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A ALDH1A1 2665/4885TSHR 3163/4885TP53 4840/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ALDH1A1 2665/4885TSHR 3163/4885TP53 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.